Open Nav

News

01-02-2018

CMS Issues Permanent P-Code P9100 Allowing Outpatient Hospital Billing of the Verax PGD® Test

03-15-2016

New Draft FDA Guidance recommends secondary testing with rapid tests and Safety Measure testing for 7-day dating

02-22-2016

Verax Biomedical Announces Appointment of Paul D. Mintz, M.D. as Senior Vice President and Chief Medical Officer

10-20-2015

FDA Clearances Allow Implementation of 7-Day Platelets in the U.S. with the Platelet PGD Test

05-26-2015

Verax Biomedical Gains FDA Clearance for Expanded Platelet Safety Measure Testing Indications

12-09-2014

FDA publishes Draft Guidance outlining need and approaches for testing platelets with rapid tests for bacterial contamination

12-01-2014

Verax files 510 (k) for 2 additional platelet types, also modifies current product labeling

10-09-2013

Verax Biomedical Closes $12MM Funding Round

07-31-2012

Verax Platelet PGD® Test Cited as Important Safety Measure to Identify Contaminated Platelets Before They Reach Patients

07-17-2012

AABB hosts conference on secondary testing for bacterial contamination in platelets

The PGD testing system

The Company's first product is the Platelet PGD Test – a rapid test for the detection of bacterial contamination in platelets.

Learn More